Nanjing Anji Biological Technology Co., Ltd

Other

Jiangsu Rongtai Biotech Co., Ltd.

Xu, Hanmei

Hanmei Xu

Chunyan Pu

Zhian Kang

Dong Wang

Chen Liu

Erhao Zhang

Joseph Martinez Jean Alphonse

The present disclosure discloses use of a polypeptide, relating to the field of biopharmaceuticals. The polypeptide comprises the following domains: Pro-Arg-Cys-X-Y-Gly-Glu, where X is Trp or Tyr, and Y is Arg or Cys; and Arg-Gly-Ala-Asp-Arg-Ala; or a sequence of any amino acid mutated in the foregoing domains. The polypeptide can be used for treating various fibrosis diseases and symptoms, including pulmonary fibrosis, hepatic fibrosis, myelofibrosis, renal fibrosis, myocardial fibrosis, skin fibrosis, and lung tissue lesions.

Polypeptide and use thereof

Disclosed is a polypeptide capable of prolonging the lifespan of, or pharmaceutically acceptable salts thereof. The polypeptide has an amino acid sequence XKFAA SEQ ID NO:) (X: any amino acid, preferably T/A). Further, after one or more amino acids on the foregoing polypeptide sequence are deleted, substituted, or added, the resulting polypeptide or the pharmaceutically acceptable salts thereof still have the anti-aging activity. The polypeptide has the effect of prolonging the lifespan ofand anti-aging, and also has the function of enhancing the ability of movement behavior, improving the anti-stress ability, and alleviating the decline of movement ability in the aging process.

Polypeptide having anti-aging activity, and application thereof

The present disclosure discloses use of a fused polypeptide with multifunctional activities. In the fused polypeptide with multifunctional activities, the polypeptide contains the following domains: Pro-Arg-Cys-X-Y-Gly-Glu, where X is Trp or Tyr, and Y is Arg or Cys; and Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp; or a sequence of any amino acid mutated in the foregoing domains. The fused polypeptide can be used for treating various fibrosis diseases and symptoms, including pulmonary fibrosis, hepatic fibrosis, skin fibrosis, renal fibrosis, myocardial fibrosis, and lung tissue lesions.

Fused polypeptide with multifunctional activities and use thereof

The present invention discloses a recombinant fused polypeptide, a preparation method therefor, and use thereof. The recombinant fused polypeptide is represented by the following general formula: X-linker1-Y; Y-linker1-X; X-linker2-Y; Y-linker2-X, where X is PRCWRGEGGGGIVRRADRAAVPGGGGRGD; and Y is Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL. The recombinant fused polypeptide according to the present invention can treat various fibrosis diseases and symptoms, and therapeutic use includes anti-pulmonary fibrosis, anti-hepatic fibrosis, anti-skin fibrosis, anti-renal fibrosis, anti-myocardial fibrosis, and resistance to lung tissue lesions.

Recombinant fused polypeptide and use thereof

The present invention discloses a novel switchable dual chimeric antigen receptor-T (sdCAR-T) cell and a construction method and use thereof, which fall within the field of cellular immunotherapy for tumors. The dual chimeric antigen receptor consists of a first chimeric antigen receptor for MSLN and a second chimeric antigen receptor for FITC. A dual-targeted functional T cells regulated by specific exogenous bifunctional molecules is constructed, and the exogenous molecules are used to preliminarily discuss the in vivo and in vitro activity of the dual chimeric antigen receptor-T cell. By means of in vitro and in vivo tests, it is confirmed that the activation mode of the constructed CAR-T cell is controlled by the combination of endogenous tumor antigens and exogenous bifunctional molecules, and this combined regulation mode can significantly improve the safe application of CAR-T cell immunotherapy.

Dual chimeric antigen receptor-t cell which can be regulated, construction method therefor and use thereof

The invention discloses a fusion protein, a preparation method thereof and application thereof in preparing ophthalmic disease treatment, anti-inflammation and anti-tumor medicament, and belongs to the field of biopharmaceutical technology. The present invention uses a flexible (F) or rigid (R) linker to fuse two polypeptides to respectively obtain two bifunctional fusion proteins, namely two multi-functional fusion protein macromolecules obtained by linking antiangiogenesis polypeptides HM-3, interleukin 4 and immunoglobulin Fc fragments via an amino acid linker, which can improve drug efficacy, prolong half-life and enhance stability, has the characteristics of strong effect, low toxicity and the like, and can be used for the prevention and treatment of solid tumors and various types of inflammations and neovascular ophthalmic diseases. The fusion protein is expressed in a eukaryotic cell by a genetic engineering method and purified by affinity chromatography or the like.

Fusion protein, preparation method therefor and application thereof in preparing ophthalmic disease treatment, anti-inflammation and anti-tumor medicament

The invention discloses a fusion protein, preparation method thereof and use thereof and belongs to the field of biopharmaceutical technology. The fusion protein according to the present invention has anti-tumor, anti-autoimmune diseases and anti-inflammatory functions, and therapeutic effects on ophthalmic diseases. According to the long-acting, multifunctional fusion protein of the present invention, the EDSM-Y or EDSM-X polypeptide is fused to the antibody immunoglobulin Fc fragment by a flexible linker so as to obtain the fusion proteins I-V, which can improve the efficacy, prolong the half-life and enhance stability, have characteristics of strong effect, low toxicity and the like, and can be used for the prevention and treatment of solid tumors and various types of inflammation and neovascular ophthalmic diseases. The fusion protein is expressed in a prokaryotic cell or a eukaryotic cell by a genetic engineering method, and the expressed fusion protein is obtained by affinity chromatography.

Fusion protein, preparation method therefor and use thereof

A polypeptide with analgesic activity and use thereof is disclosed. The polypeptide has the amino acid sequence of X-X-Cys-Ser-Thr-Pro-Pro-X-X-Val-Leu-Tyr-X(SEQ ID NO: 1), or a pharmaceutically acceptable salt thereof, wherein the Xis Gly or deleted, the Xis one of Ser or Lys; the Xis one of d-Cys or Ser or Asp, the Xis Ala or deleted; and the Xis Cys or Ser. One pair of disulfide bonds are formed between two cysteines in the sequence. The polypeptide has good inhibitory effects on physicochemical irritating pain and pathological and neuropathic pain, and has good analgesic effects in various experimental models. The specific effects of the polypeptide are to significantly increase the threshold of pain of mice, prolong the heat tolerance time of mice, and the adverse reactions such as spontaneous movement and excitability of mice are lower than normal values.

Polypeptide having analgesic activity and use thereof

A polyethylene glycol-modified angiogenesis inhibitor HM-1 and its application are disclosed. The polypeptide sequence is mPEG-Arg-Gly-Ala-Asp-Arg-Ala-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO: 1), and mPEG . . . is chosen from mPEG-SC, mPEG2-NHS, mPEG-ALD or mPEG-bALD, with a molecular weight range of 500&#x2dc;40000. The polypeptide has been modified by polyethylene glycol, has the capacity to inhibit vascular endothelial cell migration and integrin affinity and binding, and can be used for the prevention and treatment of tumors, various types of inflammation, and neovascular eye diseases. The polyethylene glycol-modified angiogenesis inhibitor disclosed by the present invention is prepared by a synthetic method.

Polyethylene glycol-modified angiogenesis inhibitor HM-1 and application thereof

A series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity is provided. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis. Specifically, said series of integrin blockers include polypeptide I, polypeptide II and polypeptide III (see SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3) that can be adopted in treatment of solid tumors and rheumatoid arthritis. This invention also relates to application of these three integrin-blocking polypeptides in preparation of anti-tumor drugs, wherein the tumors that can be treated include those primary or secondary cancers originated from head and neck region or other organs such as brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gallbladder, colon, rectum, ovary, cervix, uterus, prostate, bladder and testicle, as well as melanoma and sarcomas.

Growing community of inventors

Nanjing, China

Hanmei Xu